Potential clinical use of miRNA molecules in the diagnosis of prostate cancer

[1] Aghdam S.G., Ebrazeh M., Hemmatzadeh M., Seyfizadeh N., Shabgah A.G., Azizi G., Ebrahimi N., Babaie F., Mohammadi H.: The role of microRNAs in prostate cancer migration, invasion and metastasis. J. Cell. Physiol., 2019; 234: 9927–9942 AghdamS.G. EbrazehM. HemmatzadehM. SeyfizadehN. ShabgahA.G. AziziG. EbrahimiN. BabaieF. MohammadiH. The role of microRNAs in prostate cancer migration, invasion and metastasis J. Cell. Physiol. 2019 234 9927 9942 10.1002/jcp.27948 Search in Google Scholar

[2] Alford A.V., Brito J.M., Yadav K.K., Yadav S.S., Tewari A.K., Renzulli J.: The use of biomarkers in prostate cancer screening and treatment. Rev. Urol., 2017; 19: 221–234 AlfordA.V. BritoJ.M. YadavK.K. YadavS.S. TewariA.K. RenzulliJ. The use of biomarkers in prostate cancer screening and treatment Rev. Urol. 2017 19 221 234 Search in Google Scholar

[3] Bayraktar R., Van Roosbroeck K., Calin G.A.: Cell-to-cell communication: MicroRNAs as hormones. Mol. Oncol., 2017; 11: 1673–1686 BayraktarR. Van RoosbroeckK. CalinG.A. Cell-to-cell communication: MicroRNAs as hormones Mol. Oncol. 2017 11 1673 1686 10.1002/1878-0261.12144 Search in Google Scholar

[4] Boerrigter E., Groen L.N., Van Erp N.P., Verhaegh G.W., Schalken J.A.: Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. Expert Rev. Mol. Diagn., 2020; 20: 219–230 BoerrigterE. GroenL.N. Van ErpN.P. VerhaeghG.W. SchalkenJ.A. Clinical utility of emerging biomarkers in prostate cancer liquid biopsies Expert Rev. Mol. Diagn. 2020 20 219 230 10.1080/14737159.2019.1675515 Search in Google Scholar

[5] Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., D’Urso L., Pagliuca A., Biffoni M., Labbaye C., Bartucci M., Muto G., Peschle C., De Maria R.: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med., 2008; 14: 1271–1277 BonciD. CoppolaV. MusumeciM. AddarioA. GiuffridaR. MemeoL. D’UrsoL. PagliucaA. BiffoniM. LabbayeC. BartucciM. MutoG. PeschleC. De MariaR. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities Nat. Med. 2008 14 1271 1277 10.1016/S0022-5347(09)60542-5 Search in Google Scholar

[6] Bonci D., Coppola V., Patrizii M., Addario A., Cannistraci A., Francescangeli F., Pecci R., Muto G., Collura D., Bedini R., Zeuner A., Valtieri M., Sentinelli S., Benassi M.S., Gallucci M. i wsp.: A microRNA code for prostate cancer metastasis. Oncogene, 2016; 35: 1180–1192 BonciD. CoppolaV. PatriziiM. AddarioA. CannistraciA. FrancescangeliF. PecciR. MutoG. ColluraD. BediniR. ZeunerA. ValtieriM. SentinelliS. BenassiM.S. GallucciM. A microRNA code for prostate cancer metastasis Oncogene 2016 35 1180 1192 10.1038/onc.2015.176480347326073083 Search in Google Scholar

[7] Bucay N., Bhagirath D., Sekhon K., Yang T., Fukuhara S., Majid S., Shahryari V., Tabatabai Z., Greene K.L., Hashimoto Y., Shiina M., Yamamura S., Tanaka Y., Deng G., Dahiya R., Saini S.: A novel micro-RNA regulator of prostate cancer epithelial-mesenchymal transition. Cell Death Differ., 2017; 24: 1263–1274 BucayN. BhagirathD. SekhonK. YangT. FukuharaS. MajidS. ShahryariV. TabatabaiZ. GreeneK.L. HashimotoY. ShiinaM. YamamuraS. TanakaY. DengG. DahiyaR. SainiS. A novel micro-RNA regulator of prostate cancer epithelial-mesenchymal transition Cell Death Differ. 2017 24 1263 1274 10.1038/cdd.2017.69552017428498363 Search in Google Scholar

[8] Chen D.Q., Yu C., Zhang X.F., Liu Z.F., Wang R., Jiang M., Chen H., Yan F., Tao M., Chen L.B., Zhu H., Feng J.F.: HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9. Ther. Adv. Med. Oncol., 2018; 10: 1758835918783132 ChenD.Q. YuC. ZhangX.F. LiuZ.F. WangR. JiangM. ChenH. YanF. TaoM. ChenL.B. ZhuH. FengJ.F. HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9 Ther. Adv. Med. Oncol. 2018 10 1758835918783132 10.1177/1758835918783132604867230034549 Search in Google Scholar

[9] Chen L., Cao H., Feng Y.: MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1. World J. Urol., 2018; 36: 357–365 ChenL. CaoH. FengY. MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1 World J. Urol. 2018 36 357 365 10.1007/s00345-017-2143-029204706 Search in Google Scholar

[10] Cochetti G., Rossi de Vermandois J.A., Maulà V., Giulietti M., Cecati M., Del Zingaro M., Cagnani R., Suvieri C., Paladini A., Mearini E.: Role of miRNAs in prostate cancer: Do we really know everything? Urol. Oncol., 2020; 38: 623–635 CochettiG. Rossi de VermandoisJ.A. MaulàV. GiuliettiM. CecatiM. Del ZingaroM. CagnaniR. SuvieriC. PaladiniA. MeariniE. Role of miRNAs in prostate cancer: Do we really know everything? Urol. Oncol. 2020 38 623 635 10.1016/j.urolonc.2020.03.00732284256 Search in Google Scholar

[11] Colden M., Dar A.A., Saini S., Dahiya P.V., Shahryari V., Yamamura S., Tanaka Y., Stein G., Dahiya R., Majid S.: MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis., 2018; 8: e2572 ColdenM. DarA.A. SainiS. DahiyaP.V. ShahryariV. YamamuraS. TanakaY. SteinG. DahiyaR. MajidS. MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2 Cell Death Dis. 2018 8 e2572 10.1038/cddis.2017.15538639328125091 Search in Google Scholar

[12] Dong Q., Meng P., Wang T., Qin W., Qin W., Wang F., Yuan J., Chen Z., Yang A., Wang H.: MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One, 2010; 5: e10147 DongQ. MengP. WangT. QinW. QinW. WangF. YuanJ. ChenZ. YangA. WangH. MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2 PLoS One 2010 5 e10147 10.1371/journal.pone.0010147285468520418948 Search in Google Scholar

[13] Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F.: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer., 2019; 144: 1941–1953 FerlayJ. ColombetM. SoerjomataramI. MathersC. ParkinD.M. PiñerosM. ZnaorA. BrayF. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods Int. J. Cancer. 2019 144 1941 1953 10.1002/ijc.3193730350310 Search in Google Scholar

[14] Filella X., Foj L.: miRNAs as novel biomarkers in the management of prostate cancer. Clin. Chem. Lab. Med., 2017; 55: 715–736 FilellaX. FojL. miRNAs as novel biomarkers in the management of prostate cancer Clin. Chem. Lab. Med. 2017 55 715 736 10.1515/cclm-2015-107326751899 Search in Google Scholar

[15] Fu X., Meng Z., Liang W., Tian Y., Wang X., Han W., Lou G., Wang X., Lou F., Yen Y., Yu H., Jove R., Huang W.: miR-26 enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene, 2014; 33: 4296–4306 FuX. MengZ. LiangW. TianY. WangX. HanW. LouG. WangX. LouF. YenY. YuH. JoveR. HuangW. miR-26 enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis Oncogene 2014 33 4296 4306 10.1038/onc.2013.385487328924056962 Search in Google Scholar

[16] Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafrè S.A., Farace M.G.: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem., 2007; 282: 23716–23724 GalardiS. MercatelliN. GiordaE. MassaliniS. FrajeseG.V. CiafrèS.A. FaraceM.G. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1 J. Biol. Chem. 2007 282 23716 23724 10.1074/jbc.M70180520017569667 Search in Google Scholar

[17] Goto Y., Kojima S., Nishikawa R., Enokida H., Chiyomaru T., Kinoshita T., Nakagawa M., Naya Y., Ichikawa T., Seki N.: The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget, 2014; 5: 7748–7759 GotoY. KojimaS. NishikawaR. EnokidaH. ChiyomaruT. KinoshitaT. NakagawaM. NayaY. IchikawaT. SekiN. The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer Oncotarget 2014 5 7748 7759 10.18632/oncotarget.2294420215825115396 Search in Google Scholar

[18] Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J.: The miR–200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol., 2008; 10: 593–601 GregoryP.A. BertA.G. PatersonE.L. BarryS.C. TsykinA. FarshidG. VadasM.A. Khew-GoodallY. GoodallG.J. The miR–200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 Nat. Cell Biol. 2008 10 593 601 10.1038/ncb172218376396 Search in Google Scholar

[19] Gu H., Liu M., Ding C., Wang X., Wang R., Wu X., Fan R.: Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1. Cancer Med., 2016; 5: 1174–1182 GuH. LiuM. DingC. WangX. WangR. WuX. FanR. Hypoxia-responsive miR-124 and miR-144 reduce hypoxia-induced autophagy and enhance radiosensitivity of prostate cancer cells via suppressing PIM1 Cancer Med. 2016 5 1174 1182 10.1002/cam4.664492437626990493 Search in Google Scholar

[20] Hao P., Kang B., Yao G., Hao W., Ma F.: MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC. Oncol. Lett., 2018; 15: 4323–4329 HaoP. KangB. YaoG. HaoW. MaF. MicroRNA-211 suppresses prostate cancer proliferation by targeting SPARC Oncol. Lett. 2018 15 4323 4329 10.3892/ol.2018.7877583585729541199 Search in Google Scholar

[21] Hsieh I.S., Chang K.C., Tsai Y.T., Ke J.Y., Lu P.J., Lee K.H., Yeh S.D., Hong T.M., Chen Y.L.: MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis, 2013; 34: 530–538 HsiehI.S. ChangK.C. TsaiY.T. KeJ.Y. LuP.J. LeeK.H. YehS.D. HongT.M. ChenY.L. MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway Carcinogenesis 2013 34 530 538 10.1093/carcin/bgs37123188675 Search in Google Scholar

[22] Hu B., Jin X., Wang J.: MicroRNA-212 targets mitogen-activated protein kinase 1 to inhibit proliferation and invasion of prostate cancer cells. Oncol. Res., 2018; 26: 1093–1102 HuB. JinX. WangJ. MicroRNA-212 targets mitogen-activated protein kinase 1 to inhibit proliferation and invasion of prostate cancer cells Oncol. Res. 2018 26 1093 1102 10.3727/096504018X15154112497142784474829321092 Search in Google Scholar

[23] Kojima S., Enokida H., Yoshino H., Itesako T., Chiyomaru T., Kinoshita T., Fuse M., Nishikawa R., Goto Y., Naya Y., Nakagawa M., Seki N.: The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J. Hum. Genet., 2014; 59: 78–87 KojimaS. EnokidaH. YoshinoH. ItesakoT. ChiyomaruT. KinoshitaT. FuseM. NishikawaR. GotoY. NayaY. NakagawaM. SekiN. The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer J. Hum. Genet. 2014 59 78 87 10.1038/jhg.2013.12124284362 Search in Google Scholar

[24] Lin H.M., Nikolic I., Yang J., Castillo L., Deng N., Chan C.L., Yeung N.K., Dodson E., Elsworth B., Spielman C., Lee B.Y., Boyer Z., Simpson K.L., Daly R.J., Horvath L.G., Swarbrick A.: MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. Sci. Rep., 2018; 8: 7820 LinH.M. NikolicI. YangJ. CastilloL. DengN. ChanC.L. YeungN.K. DodsonE. ElsworthB. SpielmanC. LeeB.Y. BoyerZ. SimpsonK.L. DalyR.J. HorvathL.G. SwarbrickA. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer Sci. Rep. 2018 8 7820 10.1038/s41598-018-26050-y595991129777112 Search in Google Scholar

[25] Lin P.C., Chiu Y.L., Banerjee S., Park K., Mosquera J.M., Giannopoulou E., Alves P., Tewari A.K., Gerstein M.B., Beltran H., Melnick A.M., Elemento O., Demichelis F., Rubin M.A.: Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res., 2013; 73: 1232–1244 LinP.C. ChiuY.L. BanerjeeS. ParkK. MosqueraJ.M. GiannopoulouE. AlvesP. TewariA.K. GersteinM.B. BeltranH. MelnickA.M. ElementoO. DemichelisF. RubinM.A. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression Cancer Res. 2013 73 1232 1244 10.1158/0008-5472.CAN-12-2968356373423233736 Search in Google Scholar

[26] Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., Patrawala L., Yan H., Jeter C., Honorio S., Wiggins J.F., Bader A.G., Fagin R., Brown D., Tang D.G.: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat. Med., 2011; 17: 211–215 LiuC. KelnarK. LiuB. ChenX. Calhoun-DavisT. LiH. PatrawalaL. YanH. JeterC. HonorioS. WigginsJ.F. BaderA.G. FaginR. BrownD. TangD.G. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 Nat. Med. 2011 17 211 215 10.1038/nm.2284307622021240262 Search in Google Scholar

[27] Liu C., Liu R, Zhang D., Deng Q., Liu B., Chao H.P., Rycaj K., Takata Y., Lin K., Lu Y., Zhong Y., Krolewski J., Shen J., Tang D.G.: MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat. Commun., 2017; 8: 14270 LiuC. LiuR ZhangD. DengQ. LiuB. ChaoH.P. RycajK. TakataY. LinK. LuY. ZhongY. KrolewskiJ. ShenJ. TangD.G. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes Nat. Commun. 2017 8 14270 10.1038/ncomms14270526424428112170 Search in Google Scholar

[28] Liu R.S., Olkhow-Mitsel E., Jeyapala R., Zhao F., Commisso K., Klotz L., Loblaw A., Liu S.K., Vesprini D., Flesher N.E., Bapat B.: Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance. J. Urol., 2018; 199: 1475–1481 LiuR.S. Olkhow-MitselE. JeyapalaR. ZhaoF. CommissoK. KlotzL. LoblawA. LiuS.K. VespriniD. FlesherN.E. BapatB. Assessment of serum microRNA biomarkers to predict reclassification of prostate cancer in patients on active surveillance J. Urol. 2018 199 1475 1481 10.1016/j.juro.2017.12.00629246734 Search in Google Scholar

[29] Liu Y.N., Yin J.J., Abou-Kheir W., Hynes P.G., Casey O.M., Fang L., Yi M., Stephens R.M., Seng V., Sheppard-Tillman H., Martin P., Kelly K.: Mir-1 and miR-200 inhibit EMT via slug-dependent and tumorigenesis via slug-independent mechanisms. Oncogene, 2013; 32: 296–306 LiuY.N. YinJ.J. Abou-KheirW. HynesP.G. CaseyO.M. FangL. YiM. StephensR.M. SengV. Sheppard-TillmanH. MartinP. KellyK. Mir-1 and miR-200 inhibit EMT via slug-dependent and tumorigenesis via slug-independent mechanisms Oncogene 2013 32 296 306 10.1038/onc.2012.58758049722370643 Search in Google Scholar

[30] Loeb S., Catalona W.J.: The prostate health index: A new test for the detection of prostate cancer. Ther. Adv. Urol., 2014; 6: 74–77 LoebS. CatalonaW.J. The prostate health index: A new test for the detection of prostate cancer Ther. Adv. Urol. 2014 6 74 77 10.1177/1756287213513488394336824688603 Search in Google Scholar

[31] Lynch S.M., McKenna M.M., Walsh C.P., McKenna D.J.: miR-24 regulates CDKN1B/p27 expression in prostate cancer. Prostate, 2016; 76: 637–648 LynchS.M. McKennaM.M. WalshC.P. McKennaD.J. miR-24 regulates CDKN1B/p27 expression in prostate cancer Prostate 2016 76 637 648 10.1002/pros.2315626847530 Search in Google Scholar

[32] Majid S., Dar A.A., Saini S., Shahryari V., Arora S., Zaman M.S., Chang I., Yamamura S., Tanaka Y., Chiyomaru T., Deng G., Dahiya R.: miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin. Cancer Res., 2013; 19: 73–84 MajidS. DarA.A. SainiS. ShahryariV. AroraS. ZamanM.S. ChangI. YamamuraS. TanakaY. ChiyomaruT. DengG. DahiyaR. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways Clin. Cancer Res. 2013 19 73 84 10.1158/1078-0432.CCR-12-2952391032423147995 Search in Google Scholar

[33] Massillo C., Dalton G.N., Farré P.L., De Luca P., De Siervi A.: Implications of microRNA dysregulation in the development of prostate cancer. Reproduction, 2017; 154: R81–R97 MassilloC. DaltonG.N. FarréP.L. De LucaP. De SierviA. Implications of microRNA dysregulation in the development of prostate cancer Reproduction 2017 154 R81 R97 10.1530/REP-17-032228878093 Search in Google Scholar

[34] Mihelich B.L., Maranville J.C., Nolley R., Peehl D.M., Nonn L.: Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort. PLoS One, 2015; 10: e0124245 MihelichB.L. MaranvilleJ.C. NolleyR. PeehlD.M. NonnL. Elevated serum microRNA levels associate with absence of high-grade prostate cancer in a retrospective cohort PLoS One 2015 10 e0124245 10.1371/journal.pone.0124245439698425874774 Search in Google Scholar

[35] Miller K.D., Nogueira L., Mariotto A.B., Rowland J.H., Yabroff K.R., Alfano C.A., Jemal A., Kramer J.L., Siegel R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin., 2019; 69: 363–385 MillerK.D. NogueiraL. MariottoA.B. RowlandJ.H. YabroffK.R. AlfanoC.A. JemalA. KramerJ.L. SiegelR.L. Cancer treatment and survivorship statistics, 2019 CA Cancer J. Clin. 2019 69 363 385 10.3322/caac.2156531184787 Search in Google Scholar

[36] Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosowa-Agadjanyan E.L., Peterson A., Noteboom J., O’Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L. i wsp.: Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008; 105: 10513–10518 MitchellP.S. ParkinR.K. KrohE.M. FritzB.R. WymanS.K. Pogosowa-AgadjanyanE.L. PetersonA. NoteboomJ. O’BriantK.C. AllenA. LinD.W. UrbanN. DrescherC.W. KnudsenB.S. StirewaltD.L. Circulating microRNAs as stable blood-based markers for cancer detection Proc. Natl. Acad. Sci. USA 2008 105 10513 10518 10.1073/pnas.0804549105249247218663219 Search in Google Scholar

[37] Ortiz-Quintero B.: Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. Cell Prolif., 2016; 49: 281–303 Ortiz-QuinteroB. Cell-free microRNAs in blood and other body fluids, as cancer biomarkers Cell Prolif. 2016 49 281 303 10.1111/cpr.12262649661227218664 Search in Google Scholar

[38] Porkka K.P., Pfeiffer M.J., Waltering K.K, Vessella R.L., Tammela T.L., Visakorpi T.: MicroRNA expression profiling in prostate cancer. Cancer Res., 2007; 67: 6130–6135 PorkkaK.P. PfeifferM.J. WalteringK.K VessellaR.L. TammelaT.L. VisakorpiT. MicroRNA expression profiling in prostate cancer Cancer Res. 2007 67 6130 6135 10.1158/0008-5472.CAN-07-053317616669 Search in Google Scholar

[39] Porzycki P., Ciszkowicz E., Semik M., Tyrka M.: Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition. Int. Urol. Nephrol., 2018; 50: 1619–1626 PorzyckiP. CiszkowiczE. SemikM. TyrkaM. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition Int. Urol. Nephrol. 2018 50 1619 1626 10.1007/s11255-018-1938-2613312730014459 Search in Google Scholar

[40] Rajendiran S., Parwani A.V., Hare R.J., Dasgupta S., Roby R.K., Vishwanatha J.K.: MicroRNA–940 suppresses prostate cancer migration and invasion by regulating MEIN1. Mol. Cancer, 2014; 13: 250 RajendiranS. ParwaniA.V. HareR.J. DasguptaS. RobyR.K. VishwanathaJ.K. MicroRNA–940 suppresses prostate cancer migration and invasion by regulating MEIN1 Mol. Cancer 2014 13 250 10.1186/1476-4598-13-250424655125406943 Search in Google Scholar

[41] Rodríguez M., Bajo-Santos C., Hessvik N.P, Lorenz S., Fromm B., Berge V., Sandvig K., Linȇ A., Llorente A.: Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol. Cancer., 2017; 16: 156 RodríguezM. Bajo-SantosC. HessvikN.P LorenzS. FrommB. BergeV. SandvigK. LinȇA. LlorenteA. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes Mol. Cancer. 2017 16 156 10.1186/s12943-017-0726-4562979328982366 Search in Google Scholar

[42] Ru P., Steele R., Newhall P., Phillips N.J., Toth K., Ray R.B.: miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol. Cancer Ther., 2012; 11: 1166–1173 RuP. SteeleR. NewhallP. PhillipsN.J. TothK. RayR.B. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling Mol. Cancer Ther. 2012 11 1166 1173 10.1158/1535-7163.MCT-12-010022402125 Search in Google Scholar

[43] Selth L.A., Das R., Townley S.L., Coutinho I., Hanson A.R., Centenera M.M., Stylianou N., Sweeney K., Soekmadji C., Jovanovic L., Nelson C.C., Zoubeidi A., Butler L.M., Goodall G.J., Hollier B.G., Gregory P.A., Tilley W.D.: A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene, 2017; 36: 24–34 SelthL.A. DasR. TownleyS.L. CoutinhoI. HansonA.R. CenteneraM.M. StylianouN. SweeneyK. SoekmadjiC. JovanovicL. NelsonC.C. ZoubeidiA. ButlerL.M. GoodallG.J. HollierB.G. GregoryP.A. TilleyW.D. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer Oncogene 2017 36 24 34 10.1038/onc.2016.18527270433 Search in Google Scholar

[44] Shi X.B., Xue L., Ma A.H., Tepper C.G., Gandour-Edwards R., Kung H.J., de Vere-White R.W.: Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene, 2013; 32: 4130–4138 ShiX.B. XueL. MaA.H. TepperC.G. Gandour-EdwardsR. KungH.J. de Vere-WhiteR.W. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells Oncogene 2013 32 4130 4138 10.1038/onc.2012.425411147923069658 Search in Google Scholar

[45] Shi X.H., Li X., Zhang H., He R.Z., Zhao Y., Zhou M., Pan S.T., Zhao C.L., Feng Y.C., Wang M., Guo X.J., Qin R.Y.: A five microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data. Sci. Rep., 2018; 8: 7638 ShiX.H. LiX. ZhangH. HeR.Z. ZhaoY. ZhouM. PanS.T. ZhaoC.L. FengY.C. WangM. GuoX.J. QinR.Y. A five microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data Sci. Rep. 2018 8 7638 10.1038/s41598-018-22493-5595597629769534 Search in Google Scholar

[46] Stuopelyte K., Daniunaite K., Bakavicius A., Lazutka J.R., Jankevicius F., Jarmalaite S.: The utility of urine-circulating miRNAs for detection of prostate cancer. Br. J. Cancer, 2016; 115: 707–715 StuopelyteK. DaniunaiteK. BakaviciusA. LazutkaJ.R. JankeviciusF. JarmalaiteS. The utility of urine-circulating miRNAs for detection of prostate cancer Br. J. Cancer 2016 115 707 715 10.1038/bjc.2016.233502377227490805 Search in Google Scholar

[47] Sun Q., Weng D., Li K., Li S., Bai X., Fang C., Luo D., Wu P., Chen G., Wei J.: MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1. Oncol. Lett., 2018; 16: 793–800 SunQ. WengD. LiK. LiS. BaiX. FangC. LuoD. WuP. ChenG. WeiJ. MicroRNA-139-5P inhibits human prostate cancer cell proliferation by targeting Notch1 Oncol. Lett. 2018 16 793 800 10.3892/ol.2018.8773601992029963147 Search in Google Scholar

[48] Tinay I., Tan M., Gui B., Werner L., Kibel A.S., Jia L.: Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. Prostate, 2018; 78: 927–937 TinayI. TanM. GuiB. WernerL. KibelA.S. JiaL. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer Prostate 2018 78 927 937 10.1002/pros.2365029748958 Search in Google Scholar

[49] Tokudome S., Ando R., Koda Y.: Discoveries and application of prostate specific antigen, and some proposals to optimize prostate cancer screening. Cancer Manag. Res., 2016; 8: 45–47 TokudomeS. AndoR. KodaY. Discoveries and application of prostate specific antigen, and some proposals to optimize prostate cancer screening Cancer Manag. Res. 2016 8 45 47 10.2147/CMAR.S98326486963727274309 Search in Google Scholar

[50] Tomlins S.A., Day J.R., Lonigro R.J., Hovelson D.H., Siddiqui J., Kunju L.P., Dunn R.L., Meyer S., Hodge P., Groskopf J., Wei J.T., Chinnaiyan A.M.: Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur. Urol., 2016; 70: 45–53 TomlinsS.A. DayJ.R. LonigroR.J. HovelsonD.H. SiddiquiJ. KunjuL.P. DunnR.L. MeyerS. HodgeP. GroskopfJ. WeiJ.T. ChinnaiyanA.M. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment Eur. Urol. 2016 70 45 53 10.1016/j.eururo.2015.04.039464472425985884 Search in Google Scholar

[51] Van Neste L., Hendriks R.J., Dijkstra S., Trooskens G., Cornel E.B., Jannink S.A., de Jong H., Hessels D., Smit F.P., Melchers W.J., Leyten G.H., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C. i wsp.: Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur. Urol., 2016; 70: 740–748 Van NesteL. HendriksR.J. DijkstraS. TrooskensG. CornelE.B. JanninkS.A. de JongH. HesselsD. SmitF.P. MelchersW.J. LeytenG.H. de ReijkeT.M. VergunstH. KilP. KnipscheerB.C. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score Eur. Urol. 2016 70 740 748 10.1016/j.eururo.2016.04.01227108162 Search in Google Scholar

[52] Wang M., Yu W., Gao J., Ma W., Frentsch M., Thiel A., Liu M., Rahman N., Qin Z., Li X.: Micro-RNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1. J. Cell Physiol., 2020; 235: 1588–1600 WangM. YuW. GaoJ. MaW. FrentschM. ThielA. LiuM. RahmanN. QinZ. LiX. Micro-RNA-487a-3p functions as a new tumor suppressor in prostate cancer by targeting CCND1 J. Cell Physiol. 2020 235 1588 1600 10.1002/jcp.2907831309555 Search in Google Scholar

[53] Wang W., Liu J., Wu Q.: MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1. Eur. Rev. Med. Pharmacol. Sci., 2016; 20: 92–100 WangW. LiuJ. WuQ. MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1 Eur. Rev. Med. Pharmacol. Sci. 2016 20 92 100 Search in Google Scholar

[54] Wei J.T., Feng Z., Partin A.W., Brown E., Thompson I., Sokoll L., Chan D.W., Lotan Y., Kibel A.S., Busby J.E., Bidair M., Lin D.W., Taneja S.S., Viterbo R., Joon A.Y. i wsp.: Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J. Clin. Oncol., 2014; 32: 4066–4073 WeiJ.T. FengZ. PartinA.W. BrownE. ThompsonI. SokollL. ChanD.W. LotanY. KibelA.S. BusbyJ.E. BidairM. LinD.W. TanejaS.S. ViterboR. JoonA.Y. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? J. Clin. Oncol. 2014 32 4066 4073 10.1200/JCO.2013.52.8505426511725385735 Search in Google Scholar

[55] Williams L.V., Veliceasa D., Vinokour E., Volpert O.V.: miR-200b inhibits prostate cancer EMT, growth and metastasis. PLoS One, 2013; 8: e83991 WilliamsL.V. VeliceasaD. VinokourE. VolpertO.V. miR-200b inhibits prostate cancer EMT, growth and metastasis PLoS One 2013 8 e83991 10.1371/journal.pone.0083991387713624391862 Search in Google Scholar

[56] Xu L., Zhong J., Guo B., Zhu Q., Liang H., Wen N., Yun W., Zhang L.: miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1. Tumour Biol., 2016; 37: 12023–12032 XuL. ZhongJ. GuoB. ZhuQ. LiangH. WenN. YunW. ZhangL. miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1 Tumour Biol. 2016 37 12023 12032 10.1007/s13277-016-5058-227164937 Search in Google Scholar

[57] Yang Y., Guo J.X., Shao Z.Q.: miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study. Asian Pac. J. Trop. Med., 2017; 10: 87–91 YangY. GuoJ.X. ShaoZ.Q. miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: An experimental study Asian Pac. J. Trop. Med. 2017 10 87 91 10.1016/j.apjtm.2016.09.01128107872 Search in Google Scholar

[58] Yao J., Xu C., Fang Z., Li Y., Liu H., Wang Y., Xu C., Sun Y.: Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway. Biochem. Biophys. Res. Commun., 2016; 474: 213–219 YaoJ. XuC. FangZ. LiY. LiuH. WangY. XuC. SunY. Androgen receptor regulated microRNA miR-182-5p promotes prostate cancer progression by targeting the ARRDC3/ITGB4 pathway Biochem. Biophys. Res. Commun. 2016 474 213 219 10.1016/j.bbrc.2016.04.10727109471 Search in Google Scholar

[59] Zhang S., Cai J., Xie W., Luo H., Yang F.: miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA. Exp. Ther. Med., 2018; 16: 1499–1504 ZhangS. CaiJ. XieW. LuoH. YangF. miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA Exp. Ther. Med. 2018 16 1499 1504 10.3892/etm.2018.6296609043130112070 Search in Google Scholar

[60] Zhou Y.J., Yang H.Q., Xia W., Cui L., Xu R.F., Lu H., Xue Z., Zhang B., Tian Z.N., Cao Y.J., Xing Z.Y., Yin S., He X.Z.: Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. Life Sci., 2017; 190: 7–14 ZhouY.J. YangH.Q. XiaW. CuiL. XuR.F. LuH. XueZ. ZhangB. TianZ.N. CaoY.J. XingZ.Y. YinS. HeX.Z. Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2 Life Sci. 2017 190 7 14 10.1016/j.lfs.2017.09.02828943214 Search in Google Scholar

[61] Zhu Y., Shao S., Pan H., Cheng Z., Rui X.: MicroRNA-136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen-activated protein kinase 4. Mol. Med. Rep., 2018; 17: 4803–4810 ZhuY. ShaoS. PanH. ChengZ. RuiX. MicroRNA-136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen-activated protein kinase 4 Mol. Med. Rep. 2018 17 4803 4810 10.3892/mmr.2018.841729328468 Search in Google Scholar